New Delhi: Ranbaxy Laboratories will launch in India an anti-hypertensive drug, Olvance - the first product from its parent Daiichi Sankyo’s portfolio to be introduced through it.
Olvance (Olmesartan Medoxomil) was originally discovered by Daiichi Sankyo and its introduction in the country follows a licensing agreement between the two companies authorising the Gurgaon-based firm to promote and market the drug in India, the two companies said in a statement.
The launch of Olvance marks the beginning of a productive engagement that will harness the respective strengths of Daiichi Sankyo and Ranbaxy to establish a much stronger platform for Ranbaxy in India, Ranbaxy chairman, CEO and managing director, Malvinder Mohan Singh said.
“We are delighted with the introduction of Olvance in the Indian market by Ranbaxy, signifying our serious commitment to India. This marks our intent to scale up our innovative product introductions, in India, through Ranbaxy,” Daiichi Sankyo President and CEO Takashi Shoda said.
Olvance is a fast acting blood pressure lowering drug. It is available in more than 50 countries across the world.